Intended Use: TFE3 gene rearrangement
Rearrangements and abnormal expression of the TFE3 gene– also known as TFEA, RCCP2, RCCX1 or bHLHe33– have been observed in renal cell carcinoma subtypes, alveolar soft part carcinoma, and other tumor types.
Specimen Required
Paraffin-embed tissue (3–4-micron thick sections in positively charged/silanized slides).
Patient Preparation
- Sample collection: Tumor tissue (FFPE tissue block). Submit block/slides along with the corresponding Histopathology Report.
- Specimen preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue (3–4-micron thick sections). Fixative duration: 6-48 hours.
- Storage/Transport Temperature: Room temperature. Protect paraffin block from excessive heat. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- Unacceptable Conditions: Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens. Specimens with fixation delayed for more than one hour. Tissue fixed or less than 6 hours of greater than 48 hours.
- Remarks
- Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
5 working days
Reference Interval
————-
Interpretive Data
The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluating TFE3 gene rearrangement status.
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report